BiotechTube
Noscendo

Noscendo

Mannheim, Germany· Est.
noscendo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Noscendo is a privately held, commercial-stage diagnostics company based in Mannheim, Germany, founded in 2017. It has developed and launched DISQVER®, a proprietary AI-driven platform that analyzes cell-free DNA from blood samples using next-generation sequencing to detect a broad range of bacterial, viral, fungal, and parasitic pathogens. The company targets the critical unmet need for rapid, unbiased pathogen identification in sepsis and other complex infections, positioning itself at the intersection of advanced genomics, bioinformatics, and clinical diagnostics. Noscendo operates a B2B model, providing its testing service to hospitals and laboratories, and has established key partnerships to drive adoption and reimbursement.

Infectious Diseases

Technology Platform

DISQVER® platform combining next-generation sequencing of cell-free DNA from blood with DEEP®, a proprietary AI-powered bioinformatics engine, for unbiased pathogen detection.

Opportunities

The global push for antimicrobial stewardship creates a strong tailwind for rapid, precise diagnostic tools like DISQVER®.
Expansion into new clinical indications (e.g., endocarditis, infections in immunocompromised patients) and geographic markets (other EU countries) presents significant growth potential.
The proprietary DEEP® AI software is a scalable asset that could be licensed or adapted for other diagnostic applications.

Risk Factors

Commercial success depends on demonstrating cost-effectiveness to hospitals and navigating complex reimbursement systems.
The company faces competition from both established diagnostic giants with PCR panels and other NGS-based startups.
Regulatory pathways for NGS-based tests and AI software are evolving and could pose compliance challenges.

Competitive Landscape

Noscendo competes in the molecular infectious disease diagnostics space. Key competitors include large companies like BioMérieux (BioFire FilmArray), Roche, and Qiagen, which offer rapid, targeted multiplex PCR panels. It also faces competition from other companies developing metagenomic NGS (mNGS) solutions for infection diagnosis, such as Karius (US) and Micronoma (US), as well as broader NGS service providers. Noscendo's differentiation lies in its integrated service model and its specifically trained AI for pathogen detection from blood.

More companies in Diagnostics & Precision Medicine →More companies in Germany →